T

Telix Pharmaceuticals
TLX

Last Price

Financial Snapshot

gainify

Market Data

Market Cap
A$9.11B
EV
A$8.98B
Shares Outstanding
352.49M
Beta
2.49

Wall Street View

Analyst Rating
BUY
Analyst Target Price
A$32.05
P/E 2025E
63.65x
P/Revenue 2025E
7.14x

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About Telix Pharmaceuticals Limited

gainify

T

Telix Pharmaceuticals Limited

TLX

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United Stat...

Sector

Healthcare

Industry

Biotechnology

CEO

Behrenbruch, Christian

Employees

423

IPO Date

2017-11-14

Headquarters

55 Flemington Road, Suite 401, North Melbourne, Victoria, 3051, Australia

gainify
mailcontactcontact
powered-by-sp

NEWSLETTER

COMPANY

© Copyright 2025, All Rights Reserved